Essential Group, Inc. Appoints New Strategic Director of Essential Patient Recruitment(TM) Services
Posted on: Monday, 14 November 2005, 15:00 CST
GURNEE, Ill., Nov. 14 /PRNewswire/ -- Essential Group, Inc. today announced that Lani Hashimoto Little, has joined the company as Strategic Director, Essential Patient Recruitment(TM). Her responsibilities include strategic development, proposal support, and impact analysis for all patient recruitment campaigns for sponsors and sites. Ms. Hashimoto Little works closely with the Essential Patient Recruitment operations team while evaluating service improvements and new capabilities.
"Lani has managed patient recruitment programs in a wide spectrum of therapeutic categories as well as patient and physician-directed messaging. She is a recognized industry expert in the field of patient recruitment and is an experienced speaker on patient recruitment issues and solutions. Lani's leadership will enhance our fast growing patient recruitment service that has now executed on over 1,000 patient recruitment programs since 1996," stated Lee Jones, President & CEO of Essential Group, Inc.
Ms. Hashimoto Little holds a bachelor's degree in French Education from Western Carolina University and comes to Essential Patient Recruitment(TM) with over 10 years of patient recruitment experience. Before joining Essential, Lani was Vice President, Recruitment Services responsible for managing operations for a patient recruitment services firm. Additionally, she has focused on patient privacy, internet initiatives, and global expansion of patient recruitment initiatives.
About Essential Group, Inc.
Essential Group, Inc., is the operating company for Essential(TM) CRO, Essential Patient Recruitment(TM), and AmericasDoctor(TM). Essential(TM) is a full-service, specialty CRO that delivers success through outstanding clinical study execution, therapeutic expertise, and relationship management in the areas of urology, gastroenterology, neuroscience, and women's health. Our customized clinical research solutions, coupled with our unparalleled therapeutic experience database, offer best-in-class skills and services necessary to successfully support your clinical research program. Essential Patient Recruitment(TM) is a leading patient recruitment service that provides innovative customized approaches to recruiting patients for all phases and types of clinical trials in drug, device and nutritional industries using its DELIVER methodology. This DELIVER method is uniquely supported by over a decade's worth of expertise at understanding the unique study site physiology required to succeed at randomizing patients into studies at the study site. AmericasDoctor(TM) is a leading affiliated site management network in the U.S. and provides pharmaceutical, biotechnology, and device companies a single source for conducting Phase I-IV clinical research in four therapeutic areas: urology, gastroenterology, CNS, and women's health. By integrating a leading community-based physician network and comprehensive site management expertise, AmericasDoctor(TM) provides a broad range of services fundamental to executing well-controlled clinical trials expeditiously and economically.
http://www.essentialgroupinc.com/
Except for the historical information contained in this presentation, statements in this presentation may be considered forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the anticipated impact of the company's business plan on its future earnings and cash flows. Actual results may differ materially from those contained in the forward-looking statements in this presentation, and you should be aware that these forward-looking statements are subject to risks and uncertainties that are beyond the company's control. These risks and uncertainties include the company's ability to operate within budgeted expense, the company's ability to successfully implement its business plan, general economic conditions, the impact of competition, quarterly fluctuations in operating results, the customers' acceptance of new services, the retention of key employees, investments in new business opportunities, and the company's ability to make infrastructure investments at a lower cost per customer than its competition. Certain of these and other risks associated with AmericasDoctor's business are discussed from time to time in its public filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this presentation, and there is no assurance that the results and events contemplated by the forward-looking information contained in this presentation will in fact transpire.
Essential Group, Inc.
CONTACT: Lisa Elsen of Essential Group, Inc., +1-847-855-7668,lelsen@essentialgroupinc.com
Web site: http://www.essentialgroupinc.com/http://www.americasdoctor.com/
Source: PRNewswire
Related Articles
- Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
- Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace
- Praxis Launches Patient Recruitment Campaign For 2nd Protocol of Women's Health Research Program
- Praxis' Patient Recruitment Campaign Saves 380 Days Off Enrollment for Women's Health Study
- Praxis Launches Patient Recruitment Program for Women's Health Medical Research Studies
- Cell Genesys Completes Patient Recruitment for First Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
- 'Reinventing Patient Recruitment: Revolutionary Ideas for Clinical Trial Success' Is A Definitive Guide to Planning, Implementing, and Evaluating Recruitment Strategies and Campaigns Globally
- Patient Recruitment and Retention in Clinical Trials is Likely to Remain an Area of Heightened Concern for Pharmaceutical Companies for at Least the Next Five Years
- Advitech Completes Recruitment for Its Second Clinical Study on Oral Treatment for Psoriasis
 |
 |
User Comments (0)
RSS Feeds